Aptose Biosciences Inc. – NASDAQ:APTO
Aptose Biosciences stock price today
$2.103
+1.86
+772.57%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Aptose Biosciences stock price monthly change
-66.06%
month
Aptose Biosciences stock price quarterly change
-66.06%
quarter
Aptose Biosciences stock price yearly change
-90.59%
year
Aptose Biosciences key metrics
Market Cap | 13.63M |
Enterprise value | 12.44M |
P/E | -1.2 |
EV/Sales | N/A |
EV/EBITDA | -0.19 |
Price/Sales | N/A |
Price/Book | 1.27 |
PEG ratio | -0.03 |
EPS | -6.31 |
Revenue | N/A |
EBITDA | -47.73M |
Income | -47.45M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAptose Biosciences stock price history
Aptose Biosciences stock forecast
Aptose Biosciences financial statements
| Jun 2023 | 0 | -14.12M | |
|---|---|---|---|
| Sep 2023 | 0 | -11.44M | |
| Dec 2023 | 712.20K | -12.28M | -1724.98% |
| Mar 2024 | 0 | -9.59M |
| Sep 2025 | 0 | -7.27M | |
|---|---|---|---|
| Oct 2025 | 0 | -10.37M | |
| Dec 2025 | 0 | -5.39M | |
| Dec 2025 | 0 | -11.68M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 26575000 | 12.78M | 48.12% |
|---|---|---|---|
| Sep 2023 | 20876000 | 13.1M | 62.75% |
| Dec 2023 | 12922544 | 15.80M | 122.33% |
| Mar 2024 | 12782809 | 12.64M | 98.93% |
| Jun 2023 | -13.50M | -1.96M | 1.10M |
|---|---|---|---|
| Sep 2023 | -10.53M | 12.95M | 4.90M |
| Dec 2023 | -9.50M | 1.99M | 854K |
| Mar 2024 | -11.71M | -1.98M | 11.79M |
Aptose Biosciences alternative data
| Aug 2023 | 35 |
|---|---|
| Sep 2023 | 35 |
| Oct 2023 | 35 |
| Nov 2023 | 35 |
| Dec 2023 | 35 |
| Jan 2024 | 35 |
| Feb 2024 | 35 |
| Mar 2024 | 35 |
| Apr 2024 | 35 |
| May 2024 | 35 |
| Jun 2024 | 35 |
| Jul 2024 | 35 |
Aptose Biosciences other data
100.00%
+74.92%
of APTO is owned by hedge funds
29
-19
5.33M
-17.78M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2024 | 150000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | RICE WILLIAM G. director, officer.. | Common Shares | 100,000 | $0.2 | $20,000 | ||
Purchase | RICE WILLIAM G. director, officer.. | Common Shares | 100,000 | $0.2 | $20,000 | ||
Purchase | RICE WILLIAM G. director, officer.. | Warrants | 50,000 | $0.25 | $12,500 | ||
Purchase | RICE WILLIAM G. director, officer.. | Warrants | 50,000 | $0.25 | $12,500 | ||
Purchase | SEIZINGER BERND R. director | Common Shares | 17,000 | $3.14 | $53,380 | ||
Purchase | PAYNE FLETCHER officer: SR VP & Chief Fin. Off.. | Common Shares | 10,000 | $0.68 | $6,780 | ||
Purchase | RICE WILLIAM G. director, officer.. | Common Shares | 10,000 | $0.68 | $6,830 | ||
Purchase | RICE WILLIAM G. director, officer.. | Common Shares | 10,000 | $0.68 | $6,830 | ||
Purchase | RICE WILLIAM G. director, officer.. | Common Shares | 10,000 | $0.97 | $9,680 | ||
Purchase | RICE WILLIAM G. director, officer.. | Common Shares | 10,000 | $0.97 | $9,680 |
| Patent |
|---|
Application Filling date: 2 Jun 2021 Issue date: 9 Dec 2021 |
Grant Filling date: 30 Oct 2018 Issue date: 19 Oct 2021 |
Grant Filling date: 20 Mar 2018 Issue date: 31 Aug 2021 |
Application COMBINATION THERAPY WITH 2,3-DIHYDRO-ISOINDOLE-1-ONE COMPOUNDS AND METHODS FOR TREATING PATIENTS WITH VARIOUS MUTATIONS Filling date: 2 Dec 2019 Issue date: 4 Jun 2020 |
Application Filling date: 1 Dec 2017 Issue date: 26 Mar 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 26 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Aptose Biosciences stock today?
One share of Aptose Biosciences stock can currently be purchased for approximately $2.1.
-
When is Aptose Biosciences's next earnings date?
Unfortunately, Aptose Biosciences's (APTO) next earnings date is currently unknown.
-
Does Aptose Biosciences pay dividends?
No, Aptose Biosciences does not pay dividends.
-
How much money does Aptose Biosciences make?
Aptose Biosciences has a market capitalization of 13.63M.
-
What is Aptose Biosciences's stock symbol?
Aptose Biosciences Inc. is traded on the NASDAQ under the ticker symbol "APTO".
-
What is Aptose Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aptose Biosciences?
Shares of Aptose Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aptose Biosciences's key executives?
Aptose Biosciences's management team includes the following people:
- Dr. William G. Rice Ph.D. Chairman, Pres & Chief Executive Officer(age: 66, pay: $898,830)
- Dr. Jotin Marango Ph.D., M.D. Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Chief Bus. Officer(age: 46, pay: $573,660)
- Dr. Rafael Bejar M.D., Ph.D. Senior Vice President & Chief Medical Officer(age: 53, pay: $566,920)
-
How many employees does Aptose Biosciences have?
As Jul 2024, Aptose Biosciences employs 35 workers.
-
When Aptose Biosciences went public?
Aptose Biosciences Inc. is publicly traded company for more then 33 years since IPO on 16 Mar 1992.
-
What is Aptose Biosciences's official website?
The official website for Aptose Biosciences is aptose.com.
-
Where are Aptose Biosciences's headquarters?
Aptose Biosciences is headquartered at 251 Consumers Road, Toronto, ON.
-
How can i contact Aptose Biosciences?
Aptose Biosciences's mailing address is 251 Consumers Road, Toronto, ON and company can be reached via phone at +1 650 718 5028.
Aptose Biosciences company profile:
Aptose Biosciences Inc.
aptose.comExchange:
NASDAQ
Full time employees:
35
Industry:
Biotechnology
Sector:
Healthcare
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
251 Consumers Road
Toronto, ON M2J 4R3
Toronto, ON M2J 4R3
CIK: 0000882361
ISIN: CA03835T3091
CUSIP: 03835T200
